-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Search results for: “patient perspective”
-
Patient Advocate Ivy B. Elkins Leaves Lasting Legacy
Ms. Elkins, co-founder of the EGFR Resisters advocacy group, will be remembered for her warm and energetic approach to furthering lung cancer research efforts.
-
Patient Perspective: Exercise Prescriptions Needed for Lung Cancer Patients
Runner and patient advocate Angus Pratt says running three times a week may be the antithesis of what most people expect from a lung cancer patient, but not only is it possible, it is beneficial.
-
A New Treatment Option for Early-Stage ALK+ NSCLC: Adjuvant Alectinib
In part 2 of their interview, Drs. Narjust Florez and Benjamin Solomon dig deeper into the implications of the ALINA trial, discussing endpoints, toxicities, and future directions.
-
Increased Biomarker Uptake Needed to Further Realize Potential of Precision Medicine
Drs. Christian Rolfo and Valeria Denninghoff contend that data show improvements in outcomes from personalized treatment may have stalled and that increased testing for driver genes alterations is needed.
-
Experts Debate Addition of Frontline Chemotherapy for EGFR+ NSCLC
In light of data from FLAURA2 and MARIPOSA, Drs. Suresh Ramalingam and Joshua Sabari weighed the pros and cons during the 2024 TTLC meeting.
-
Should Biomarkers Be Used in the Clinical Management of ES-SCLC?
During a recent debate, Drs. Anne Chiang and Stephen Liu offered differing perspectives on the feasibility of biomarker use in the small-cell lung cancer space.
-
Scientist, Advocate, and Leader: A Q&A with Dr. Jennifer King
Get to know IASLC’s new Chief Science Officer and learn more about the role she and her team will play in conquering thoracic cancers in the 21st century.
-
Artificial Intelligence in Thoracic Radiation Oncology: Treatment, Challenges, and Future Directions
In part 2 of our look at AI’s impact on radiotherapy, Grace Lee, MD, Fridolin Haugg, MSc, and Raymond H. Mak, MD, discuss how AI may be leveraged when delivering radiotherapy, including improving our ability to predict treatment response and adverse events.
-
Guideline Taskforce Chairs Discuss Need for Caution, Multidisciplinary Decision-Making When Using Definitive Radiotherapy for Oligometastatic NSCLC
In an interview with ILCN, Drs. Puneeth Iyengar and Matthias Guckenberger said despite a lack of phase III data in this space, science-based recommendations are needed to optimize multimodal therapy.
-
Screening Experts Outline Considerations for LDCT Screening Programs
Lead author Dr. Claudia Henschke says a recently published perspective from the IASLC Early Detection and Screening Committee explores several components of effective screening efforts, including timing between screenings.
View ILCN Archives
Provider Resources
Popular Articles